- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 27
- States / cities
- Goodyear, Arizona • Peoria, Arizona • Huntington Beach, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–33
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Maturity Onset Diabetes of the Young
- Interventions
- Liraglutide
- Drug
- Lead sponsor
- Mansa
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- SAR425899, Placebo, Liraglutide, Metformin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 23
- States / cities
- Sheffield, Alabama • Huntington Park, California • Los Angeles, California + 18 more
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
- Interventions
- Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 10 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, sitagliptin, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Escondido, California + 46 more
- Conditions
- Diabetes Mellitus
- Interventions
- To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists
- Device
- Lead sponsor
- Abbott Diabetes Care
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Miami Gardens, Florida
- Conditions
- Obesity and Obesity-related Medical Conditions, Bariatric Surgery
- Interventions
- tirzepatide, Standard of Care
- Drug · Behavioral
- Lead sponsor
- Marlene Starr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Obesity
- Interventions
- Saxenda, Placebos, RYGB
- Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
- Interventions
- Liraglutide Pen Injector [Saxenda], Medication Diary
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois